more_reports

Neuroscience Co. Enters Catalyst-Rich 2026 With Multiple Phase 2 Readouts and US$120M Financing

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE), citing upcoming Phase 2 data readouts for ALTO-101, ALTO-300, and ALTO-100, plus US$120 million financing to advance ALTO-207 in treatment-resistant depression through Phase 3.
Tags: Biotechnology / Pharmaceuticals

Biotech Company Accelerates AI Detection Breakthrough Globally

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) advanced AI-powered screening kiosks, targeting safer operations across industrial sectors.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Durham, NC Biopharma Co. Finds High-Growth Drug Opportunity

  ()
Pelthos Therapeutics Inc. (PTHS:NYSEAmerican) delivered massive growth from its drug launch, with bullish forecasts signaling upside, according to analysts.
Tags: Biotechnology / Pharmaceuticals

Life Sciences Firm Advances Massive US$2.4B Market Opportunity

  ()
Cleantech and life sciences leader BioLargo Inc. (BLGO:OTCQX) announces that clinical experiences with ViaCLYR were presented at a symposium in Hawaii.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

An AI-Powered Doctor & Patient Platform: Why This North American Provider is Gaining Market Momentum

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson explains why he likes Rocket Doctor AI Inc. (AIDR:CSE; TREIF:OTC; 939:FRA).
Tags: TechnologyBiotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Savara Inc. (SVRA:NASDAQ), citing a cleared regulatory path for Molbreevi with an August 22, 2026, PDUFA date, no planned FDA Advisory Committee, and accelerating commercial preparations targeting 1,700 accounts and 4,500 healthcare professionals ahead of a potential approval in the rare autoimmune PAP market.
Tags: Biotechnology / Pharmaceuticals

Bothell, WA Bio Co. Poised for 17-20% Revenue Growth in 2026 as Cell Therapy Market Expands

Research Report
  ()
BioLife Solutions Inc. (BLFS:NASDAQ) reported strong 2025 results. The company is now a pure-play cell processing business, expecting double-digit growth driven by expanding cell and gene therapy adoption, according to an H.C. Wainwright & Co. research note.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

A New Infection Control Platform Launched

Contributed Technical Analyst Opinion
  ()
John Newell of John Newell & Associates shares his thoughts on BioLargo Inc. (BLGO:OTCQX) to explain why he thinks the stock is a Speculative Buy.
Tags: Biotechnology / PharmaceuticalsAlternative - Cleantech

Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data

Research Report
  ()
Leede Financial maintained its rating on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), with a US$16.00 price target following updated interim Phase II SAT-3247 data from the TRAILHEAD trial in Duchenne muscular dystrophy.
Tags: Biotechnology / Pharmaceuticals

Cannabis Producer Moves to the TSX as Analyst Flags Major Expansion Potential

  ()
Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE) began trading on the Toronto Stock Exchange on March 2 after graduating from the TSX Venture Exchange. Atrium Research initiated coverage with a BUY rating and CA$3.00 target, citing best-in-class EBITDA margins of 29%.
Tags: NutraceuticalsBiotechnology / Pharmaceuticals

Medical Co.'s TULSA-PRO Installed Base Growth and CAPTAIN Trial Data Could Accelerate Adoption in 2026"

Research Report
  ()
Leede Financial maintained its rating on Profound Medical Corp. (PROF:NASDAQ; PRN:TSX), citing strong TULSA-PRO capital sales, expanding installed base, and upcoming CAPTAIN trial results at EAU meeting as key catalysts.
Tags: Medical Devices

Target Raised on CA Pharma Co. as EBITDA Margins Sustain Upward Trajectory

Research Report
  ()
Leede Financial maintains its current rating on CareRx and raised its target price, following FQ425 results showing continued sequential improvement in EBITDA, margins, and operating cash flow.
Tags: Biotechnology / Pharmaceuticals

Biotech With Groundbreaking Diabetes Treatment Secures CA$7.1M Breakthrough Financing

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) successfully secured financing transactions totaling CA$7.1 million, significantly bolstering the company's financial stability. Find out how one analyst rates the stock.
Tags: Biotechnology / Pharmaceuticals

Record Profits, a Vape Market Landgrab, and a CA$250M Facility Bought for CA$27M

Research Report
  ()
Atrium Research initiated coverage on Cannara Biotech Inc. (LOVE:TSX; LOVFF:OTCQX; BCB0:FSE), citing the company's dominant position in Quebec's new vape category, best-in-class EBITDA margins of 29%, and a capital-efficient expansion path at its Valleyfield facility that could unlock 100,000 kg of annual production capacity by FY30.
Tags: CannabisBiotechnology / Pharmaceuticals

Biotech Expands Financing to CA$2M as AI-Driven Cancer Drug Programs Advance

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) increased its previously announced financing to approximately US$2.0 million through a convertible debenture and private placement. The company stated the proceeds will support working capital needs and ongoing corporate and strategic initiatives.
Tags: Life Sciences Tools & DiagnosticsBiotechnology / Pharmaceuticals

New Data, Analyst Calls, and Pipeline Milestones Put Spotlight on Next Wave of Weight-Loss Drug Developers

  ()
Eli Lilly (LLY:NYSE), Amgen (AMGN:NASDAQ), and Structure Therapeutics (GPCR:NASDAQ) were cited in recent reports and corporate updates tied to the expanding GLP-1 and obesity treatment market. Analyst commentary, clinical developments, and pipeline milestones highlighted ongoing activity across the sector.
Tags: Biotechnology / Pharmaceuticals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biotech Company Advances Breakthrough Hyperinsulinism Treatment

  ()
Rezolute Inc. (RZLT:NASDAQ), a late-stage company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), reports its financial results and provides a business update for the three months ending December 31, 2025. Read why one analyst considers the stock a Buy.
Tags: Biotechnology / Pharmaceuticals

CleanTech Company Advances FDA-Cleared Solution Toward Big Gains

  ()
Clean technology and life sciences company BioLargo Inc. (BLGO:OTCQX) announces that its subsidiary, Clyra Medical Technologies, Inc., has received its first commercial stocking order for ViaCLYR, its FDA-cleared wound irrigation solution. Read why one analyst believes the company has made significant progress in several initiatives.
Tags: Medical DevicesBiotechnology / Pharmaceuticals

Technically Oversold with Support, Solid Patents, & A Heavyweight Board: Is This Stock Set to Soar?

Contributed Technical Analyst Opinion
  ()
Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys board and scientific advisory team of seasoned pros includes Dr. Patrick Vink (M.D., M.B.A.), Chairman of the Board, and Dr. Dan Muruve (M.D.), Chief Scientific Officer and internationally recognized nephrologist. The technical action on the charts suggests a significant surge in the stock price could be imminent.
Tags: Biotechnology / Pharmaceuticals

Experts Spotlight a Persistent Barrier in Advanced Cancer Therapies

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) outlined its AI-driven approach to brain-penetrant ATR and mTOR inhibitors during the 9th Annual DNA Damage Response Inhibitors Summit in Boston. The company also reported inbound interest in its kt-3000 series as potential payloads for antibody-drug conjugates.
Tags: Biotechnology / Pharmaceuticals

FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results

  ()
TuHURA Biosciences Inc. (HURA:NASDAQ) said the FDA granted Orphan Drug Designation to IFx-2.0 for stage IIB to stage IV cutaneous melanoma. The designation was based on data from the companys previously completed Phase 1 clinical study.
Tags: Biotechnology / Pharmaceuticals